| Popis: |
To evaluate the safety and efficacy endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS).For patients with acute cholecystitis who are poor surgical candidates, EUS-GBD using a LAMS is an important treatment alternative to percutaneous gallbladder drainage (PT-GBD).We conducted a regulatory-compliant, prospective multicenter trial at 7 tertiary referral centers in the USA and Belgium. Thirty consecutive patients with mild or moderate acute cholecystitis who were not candidates for cholecystectomy were enrolled between September 2019 and August 2021. Eligible patients had a LAMS placed transmurally with 30-to-60-day indwell if removal was clinically indicated, and 30-day follow-up post-LAMS removal. Endpoints included days until acute cholecystitis resolution, reintervention rate, acute cholecystitis recurrence rate, and procedure-related adverse events (AEs).Technical success was 93.3% (28/30) for LAMS placement and 100% for LAMS removal in 19 patients for whom removal was attempted. Five (16.7%) patients required reintervention. Mean time to acute cholecystitis resolution was 1.6±1.5 days. Acute cholecystitis symptoms recurred in 10.0% (3/30) after LAMS removal. Five (16.7%) patients died from unrelated causes. Procedure-related AEs were reported to the FDA in 30.0% (9/30) of patients, including 1 fatal event 21 days after LAMS removal; however, no AEs were causally related to the LAMS.For select patients with acute cholecystitis who are at elevated surgical risk, EUS-GBD with LAMS is an alternative to PT-GBD. It has high technical and clinical success, with low recurrence and an acceptable adverse event rate. Clinicaltrials.gov, Number: NCT03767881. |
